Zobrazeno 1 - 5
of 5
pro vyhledávání: '"59"'
Autor:
Olivia Moran, Kelly A. Metcalfe, Kristina M. Blackmore, Ophira Ginsburg, Andrea Eisen, Joanne Kotsopoulos, Martin J. Yaffe, Rochelle Demsky, Steven A. Narod, Seema Panchal, Julia A. Knight, Kevin Zbuk
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer
BMC Cancer
Background Mammographic density is one of the strongest risk factors for breast cancer. In the general population, mammographic density can be modified by various exposures; whether this is true for women a strong family history is not known. Thus, w
Autor:
Erin L. Crawford, Tian Chen, Xiaolu Zhang, Jiyoun Yeo, James C. Willey, Albert M. Levin, Thomas M. Blomquist, Sadik A. Khuder
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
Background Annual low dose CT (LDCT) screening of individuals at high demographic risk reduces lung cancer mortality by more than 20%. However, subjects selected for screening based on demographic criteria typically have less than a 10% lifetime risk
Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups
Autor:
Barbara A. Leggett, Mark Bettington, Diane McKeone, Sally-Ann Pearson, Vicki L. J. Whitehall, Catherine Bond
Publikováno v:
BMC Cancer
Background PRDM5 is an epigenetic regulator that has been recognized as an important tumour suppressor gene. Silencing of PRDM5 by promoter hypermethylation has been demonstrated in several cancer types and PRDM5 loss results in upregulation of the W
Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
Autor:
Christopher C. Benz, Christina Yau, Joe W. Gray, Dan H. Moore, Shanaz H. Dairkee, Yamei Zhou, Serenella Eppenberger-Castori, Urs Eppenberger, Karen Chew
Publikováno v:
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 59 (2007)
BMC Cancer, Vol 7, Iss 1, p 59 (2007)
Background Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods Two cell line models
Publikováno v:
BMC Cancer.
There is increasing ambiguity towards national mammographic screening programs due to varying publicized estimates of overdiagnosis, i.e., breast cancer that would not have been diagnosed in the women’s lifetime outside screening. This analysis com